Coronavirus, ok to preclinical tests for an Italian vaccine
Takis, a biotech company located in Castel Romano, near Rome, announces that it is going to test its Covid-19 vaccine on pre-clinical models. The authorization comes from the Italian Ministry of Health and represents the first step in bringing the vaccine to human use. Takis researchers are the only ones in Italy and the first in Europe to access this phase of the experimentation.
As early as the end of January, the company had announced that it wanted to make a Coronavirus vaccine. In recent weeks, our country has become one of the most affected by the Covid-19 epidemic, making the search for effective vaccines and therapies even more urgent. Today, Takis researchers reaffirm their commitment, making available their expertise in the field of vaccines and immunology. The first results of the pre-clinical trial will be available already in April. “This is a demonstration of how a group of good researchers has decided to accept a very difficult challenge and to roll up their sleeves, managing to quickly identify the best strategies for developing a vaccine and starting preclinical tests. The challenge has begun, "said Emanuele Marra, Director of the area of infectious diseases and Partner of Takis.
Takis' product is a genetic vaccine, which contains only a fragment of DNA: it is safe and induces a strong response from the immune system. It is based on a technology called electroporation, which consists of the injection into the patient's muscle followed by a very short electrical impulse which facilitates its entry into the cells and activates the immune system. The development of the vaccine is now preparing to enter a very important phase, that of pre-clinical experimentation, which will provide preliminary data on its efficacy and tolerability and will be carried out in part thanks also to the collaboration of the Spallanzani Institute in Rome, which will lead cell experiments to test the vaccine's ability to block virus replication.
"The information obtained from these initial studies will not only serve as a basis for vaccine development but will be extremely useful for creating immunization tools for the generation of neutralizing monoclonal antibodies." Giuseppe Roscilli, Director of the monoclonal antibody development area and Takis partner said.
"If the results are satisfactory, the vaccine could already be tested on humans in the autumn." - said Luigi Aurisicchio, Founder and Administrator of Takis. "Takis is the only company in Italy to have reached this point. Such an objective has been achieved thanks to the dedication of our researchers and without any type of external financing. But now Takis needs the collaboration of institutions and anyone who can contribute. For this reason, in the absence of public funding for Research, we have recently launched a crowdfunding campaign that aims to quickly collect the amount necessary to access the next stages of vaccine development, like large-scale vaccine preparation and the execution of the clinical study. " .
Takis represents an Italian excellence and is the demonstration of how important it is to invest in scientific research to preserve people's health. Hopefully Italy will understand it soon.
For the Crowdfunding campaign: https://www.gofundme.com/f/il-vaccino-italiano-contro-covid19